Modern Meadow competitors

Brian Napack is President and CEO of John Wiley and Sons (Wiley), a global research and learning company and one of the world’s leading publishers. He is the Chairman of the Association of American Publishers (AAP) which protects and promotes the central role that publishers play in enhancing culture, scholarship, education, the workforce and democracy. Brian also serves on the board of Zero-To-Three (Treasurer), a science-based advocacy organization dedicated to ensuring that all babies and toddlers have a strong start in life. Prior to joining Wiley in 2017, Brian was a Senior Advisor at Providence Equity Partners, a leading investor in media, education, information, and communication. He has served as an active member on numerous boards including those of Blackboard Inc., Houghton Mifflin Harcourt, Burning Glass, Ascend Learning, Recorded Books, Ingram Industries, myON, EDMC, and Synergis Education. Prior to joining Providence in 2012, Brian served as president of Macmillan, the global publisher, in the U.S. from 2006 to 2012. During his tenure, he oversaw businesses in education, consumer books, digital media and magazines. Prior to Macmillan, Brian was a partner at L.E.K. Consulting, a global management consulting firm, serving as co-head of its Media and Entertainment practices and leading its Publishing and Education practices. He also founded and served as CEO of ThinkBox, an education software company focused on the early childhood market. At The Walt Disney Company, Brian founded Disney Educational Publishing and was a co-founder of Disney Interactive. He has also held senior roles at Simon & Schuster, the publishing company and at A.T. Kearney, a leading management consulting company. Brian received a Master of Business Administration from Columbia University and a Bachelor of Arts from Middlebury College.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Jeff Marrazzo founded and has led the growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated, commercial gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable - until now. Under Jeff’s leadership, Spark has developed and commercialized the first gene therapy for a genetic disease in the United States while proving its technology for the delivery of genes as a medicine to both the eye and liver. In less than seven years, Jeff has built an organization of more than 450 colleagues while securing over $1 billion in capital and successfully orchestrating a merger with Roche. Jeff currently serves as a board member of Life Science Cares Philadelphia and The Rendell Center for Civics and Civic Engagement. Jeff received a B.A. in economics and B.S.E. in systems science and engineering from the University of Pennsylvania. He also holds a dual M.B.A. / M.P.A. from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded. Jeff can be found on Twitter @JeffMarrazzo.

Michael Ekkehard Hansen is the chief executive officer of Cengage Learning. Hansen specialises in the evolution of the educational publishing industry, especially the transition the industry is making from print to digital and the development of new digital product lines.

James L. Madara, MD, serves as the CEO and executive vice president of the American Medical Association, the nation’s largest physician organization. He holds the academic title of adjunct professor of pathology at Northwestern University. Since taking the reins of the AMA in 2011, Dr. Madara has helped sculpt the organization’s visionary long-term strategic plan. As an extension of this vision, he now also serves as chairman of Health2047 Inc., an independent, design-driven innovation firm based in San Francisco whose mission is to help advance the AMA’s goal of improving the health of the nation. Prior to arriving at the AMA, Dr. Madara spent the first 22 years of his career at Harvard Medical School, receiving both clinical and research training, serving as a tenured professor and as director of the NIH-sponsored Harvard Digestive Diseases Center. Following 5 years as chair of pathology at Emory, Dr. Madara served as dean of the medical school and CEO of the hospitals at the University of Chicago, bringing together the university’s biomedical research, teaching and clinical activities. While there, he oversaw the renewal of the institution’s biomedical campus and engineered significant new affiliations with community hospitals, teaching hospital systems, community clinics and national research organizations. Dr. Madara also served as senior advisor with Leavitt Partners, an innovative health care consulting and private-equity firm founded by former Secretary of Health and Human Services, Mike Leavitt. Having published more than 200 original papers and chapters, Dr. Madara has received both national and international awards, and served as editor-in-chief of the American Journal of Pathology and as president of the American Board of Pathology. In addition to Modern Healthcare consistently naming him as one of the nation’s 50 most influential physician executives, as well as one of the nation’s 100 most influential people in health care, he is a past recipient of a prestigious MERIT Award from the National Institutes of Health. He received the 2011 Davenport Award for lifetime achievement in gastrointestinal disease from the American Physiological Society and the 2011 Mentoring Award for lifetime achievement from the American Gastroenterological Society. Dr. Madara is an elected member of both the American Society of Clinical Investigation and the Association of American Physicians. He also co-chairs the Value Incentives and Systems Innovation Collaborative of the National Academy of Medicine (NAM), and is a member of NAM’s Leadership Consortium for Value & Science-Driven Health Care. Dr. Madara and his wife Vicki have 2 children, Max and Alexis.

Sejal Palande is a Joint Chief Executive Officer at American Chemical Society (ACS) and is based in Thane, Maharashtra, India. She has worked as Management Intern at robotics, Embedded System and Robotics at Team Robocon KJSIEIT, and Trainee at Vital Electronics And Manufacturing Corporate. Sejal studied at Dr Datar Science Dr Behere Arts and Shri Pilukaka Joshi Commerce College S K Patil Nagar Chiplun Tal Chiplun Dist Ratnagiri 415 605, Gharda Foundations Gharda Institute Of Technology At & Post Lavel Tal Khed Dist Ratnagiri between 2017 and 2018, and K. J. Somaiya Institute of Engineering and Information Technology between 2018 and 2021.